ElevateBio

ElevateBio

Biotechnology for cell and gene therapies

About ElevateBio

Simplify's Rating
Why ElevateBio is rated
A-
Rated A on Competitive Edge
Rated B on Growth Potential
Rated A on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

Series D

Total Funding

$1.2B

Headquarters

Waltham, Massachusetts

Founded

2017

Overview

ElevateBio operates in the biotechnology field, specifically focusing on cell and gene therapy. The company utilizes its own technologies, including gene editing and induced pluripotent stem cells (iPSC), to develop and manufacture therapies. Their products are designed to address various health issues, particularly rare and cardiometabolic diseases, and they serve clients such as other biotech firms and healthcare providers. ElevateBio distinguishes itself from competitors by offering an integrated ecosystem that combines discovery, development, manufacturing, and commercialization of therapies, which helps streamline the process and fosters scientific advancements. The company's goal is to advance the field of cell and gene therapy by providing comprehensive solutions that enhance the development and accessibility of these treatments.

Simplify Jobs

Simplify's Take

What believers are saying

  • ElevateBio's $401 million Series D funding boosts its growth and development capabilities.
  • Partnerships with Novo Nordisk and others expand ElevateBio's market reach and expertise.
  • The trend towards personalized medicine aligns with ElevateBio's integrated therapy ecosystem.

What critics are saying

  • New biomanufacturing facilities like BioForge increase competition in cell and gene therapy.
  • Reliance on large funding rounds may pose financial sustainability challenges for ElevateBio.
  • Dependence on strategic partnerships could impact revenue if collaborations fail.

What makes ElevateBio unique

  • ElevateBio integrates R&D and manufacturing for efficient cell and gene therapy commercialization.
  • The company leverages proprietary technologies like iPSC and gene editing for therapy development.
  • ElevateBio's partnerships with innovators enhance its portfolio of life-transforming medicines.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1212M

Above

Industry Average

Funded Over

4 Rounds

Notable Investors:
Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Above Average

Industry standards

$77M
$70M
Twilio
$80M
Handshake
$100M
Affirm
$401M
ElevateBio

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

0%

2 year growth

0%
Daily Energy Insider
Oct 4th, 2024
ComEd's Whole Home Electric Program electrifies 450 low-income homes in Chicago

"ComEd is proud to work hand in hand with partners like Elevate and Bickerdike to deliver innovative, clean energy technologies to communities that need them most.

TrialStat
Jan 22nd, 2024
Xcell Biosciences Announces Collaboration with ElevateBio to Advance Technology Development for Cell and Gene Therapies

In addition, Michael Paglia, Chief Technology Officer at ElevateBio's BaseCamp(R), has joined Xcellbio's Scientific Advisory Board.

Technical.ly
Sep 20th, 2023
Pitt’S Bioforge Approved, Bringing Further Tech Facilities To Hazelwood

Hazelwood’s buildup of modern manufacturing is poised to continue with city approval of the University of Pittsburgh’s plan for a biomanufacturing facility. The City Planning Commission approved a proposal for a 68-foot-tall building totaling 185,000 square feet that will house a cell- and gene-therapy facility. The approval of the BioForge building continues the high tech redevelopment of the 178-acre area known as Hazelwood Green, which includes the neighboring Mill 19, housing Carnegie Mellon University’s Manufacturing Futures Institute. And nearby is a site for which CMU recently received commission approval to build a robotics laboratory. Architecture firm HOK expects construction of the BioForge facility to begin later this year and to be completed by mid-2025. Pitt has partnered with a Massachusetts-based company, ElevateBio, and construction of BioForge is expected to cost $250 million, according to HOK

Wilson Sonsini Goodrich & Rosati
Jul 25th, 2023
Wilson Sonsini advises ElevateBio on completion of lease agreement | Wilson Sonsini

On July 21, 2023, ElevateBio, a technology-driven company built to power the development of transformative cell and gene therapies, completed the lease of its new BaseCamp manufacturing facility in Pittsburgh, per their long-term strategic partnership with the University of Pittsburgh to accelerate the development of highly innovative cell and gene therapies.

American Healthcare Leader
Jun 12th, 2023
How Bhakti Bhargava Built a Successful Finance Strategy

Five years ago, Bhakti Bhargava was one of five employees to join ElevateBio.

Recently Posted Jobs

Sign up to get curated job recommendations

ElevateBio is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update ElevateBio's jobs every 8 hours, so check again soon! Browse all jobs →